ScinoPharm Taiwan Ltd (1789.TW) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Taiwan · ISIN TW0001789006

Price
20.20 TWD
Market cap
16.27 bn TWD
P/E (2025)
118.82
P/S (2025)
5.14
Dividend yield
1.44 %
Net margin
4.33 %
Return on equity (ROE)
1.30 %
Return on assets (ROA)
1.15 %

ScinoPharm Taiwan Ltd financials

Fiscal year20242025
Revenue3.41 bn TWD3.16 bn TWD
Gross profit1.30 bn TWD1.10 bn TWD
Operating income322.71 m TWD108.91 m TWD
EBIT421.10 m TWD157.24 m TWD
Net income339.35 m TWD136.95 m TWD
Diluted EPS – continuing operations0.43 TWD0.17 TWD

Full history since 2007, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About ScinoPharm Taiwan Ltd

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.